How Does Launching a Personalized Drug Differ from Other Specialty Drugs?

Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a  personalized drug.


Transcript: Every specialty drug is different, so I think that’s what we’ve learned about specialty is there’s not a lot of cookie cutter. So I think a lot of the issues with launching a personalized drug is kind of the same for specialty. 
 
I think the great part about it, is that we can get patients to a treatment that will work for them sooner. A lot of what we go through is a lot of step therapy, which require a lot of [prior authorizations]. There is the issue that usually those therapies are more expensive, so it’s just making sure the appropriate controls are in place, but I think everyone would say they’d rather a patient start on a therapy that’s going to be effective rather than waste money on a product that’s not going to work for the patient. 
 
I think what we have to look at is we need to treat these patients as individuals and not the average patient. It gives us the opportunity to tailor a therapy specifically for that patient. I think it changes how we think about treatment a little bit and pharmacy needs to keep up with that also.




Most Popular

Related Articles

A data-centric approach is vital for patients with complex conditions, particularly in determining what has worked well and anticipating what medical or pharmacy care is required for effective outcomes in the future.
The shift from fee-based, volume-driven care to value-based, patient-centered care and the growth of specialty pharmaceuticals are propelling us all into uncharted territory, no matter what role you play in health care.
Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$